Introducing Altavita®
Comprehensive care for a broad range of patients – adults, adolescents, children, pregnancy and breastfeeding and those with swallowing difficulties.¹⁻⁵
Full range of Altavita SmPC’s available on medicines.ie or www.ema.europa.eu
* Doses of 1,000 – 2,000 IU/day may be required to prevent deficiency in some women (see SmPC’s for details of patients at risk of vitamin D Deficiency). Even higher doses may be required during breast-feeding if women choose not to give the infant a vitamin D supplement. †Vitamin D deficiency = 25 (OH) D 25 nmol/l (See SmPC’s)
Altavita D3 is indicated for the Prevention and Treatment of Vitamin D Deficiency ¹⁻⁵
Recommended Dose for the Treatment of Vitamin D Deficiency
1 x Altavita 50,000 IU capsule weekly for 6 – 8 weeks. 4
Recommended Dose for the Prevention of Vitamin D Deficiency
1 x Altavita 1,000 IU capsule daily in at risk groups. 1
ESCEO Working Group Update
According to an update from the ESCEO Working Group 1000 iu daily should be recommended in patients at increased risk of vitamin D deficiency.6
Click here for further information about patients who are at risk of vitamin D deficiency
- Consilient Health Ltd, Altavita® D3 1,000 IU soft capsules, SPC – available on medicines.ie
- Consilient Health Ltd, Altavita® D3 7,000 IU soft capsules, SPC – available on medicines.ie
- Consilient Health Ltd, Altavita® D3 25,000 IU soft capsules, SPC– available on medicines.ie
- Consilient Health Ltd, Altavita®D3 50,000 IU soft capsules, SPC – available on medicines.ie
- Consilient Health Ltd, Altavita® D3 25,000 IU oral solution, SPC – available on medicines.ie
- Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group. Aging Clinical and Experimental Research (2022) 34:2603–2623 https://doi.org/10.1007/s40520-022-02279-6
IE-ALT-351(4) March 2026
Adverse events should be reported. Reporting forms and information are available from HPRA Pharmacovigilance on the HPRA website www.hpra.ie.
Adverse events should also be reported to Consilient Health at drugsafety@consilienthealth.com or 012057766.
The information on this website is intended for Healthcare Professionals who practice in the Republic of Ireland only.